| Co-Chairs |
|
Keith T. Flaherty, MD
Director, Developmental Therapeutics
Lecturer, Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, MA
|
|
Patricia LoRusso, DO
Professor of Medicine
Chief Researcher
Director, Phase I Clinical Trials
Barbara Ann Karmanos Cancer Institute
Wayne State University
Detroit, MI
|
| Other Expert Faculty |
|
Paul B. Chapman, MD
Attending Physician
Melanoma/Sarcoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
|
|
Aleksandar Sekulic, MD, PhD
Assistant Professor of Dermatology
Mayo Clinic in Arizona
Scottsdale, Arizona
|
|
Jeffery S. Weber, MD, PhD
Director, Donald A. Adam
Comprehensive Melanoma Research Center
Senior Member, Moffitt Cancer Center
Professor and Associate Chair
Department of Oncologic Sciences
University of South Florida
Tampa, FL
|
| |
|
|
Click here for resources from the Global Resource for Advancing Cancer Education (GRACE).
|
|
|
|
CME-Accredited Webcasts, Presentation and Audio Downloads
The New Paradigm for Managing Cutaneous Malignancies: Targeted and Immunotherapy
|
You may participate in any or all of the sessions for CME credit or a Certificate of Attendance after you review the required ACCME (Accreditation Council on Continuing Medical Education) information on this page.
|
|
Menu
|
|
Please read the Overview, Learning Objectives, and Faculty Disclosures before you continue to the CME-Accredited Activity. This is an Accreditation Council for Continuing Medical Education (ACCME®) requirement. When you are finished please scroll to the bottom of this page and click the link stating that you have read and understood the faculty disclosures.
Overview of This CME-Accredited Educational Activity
Your Options for Methods of Participation are:
- View and/or listen to any of the sessions (listed below) via an Adobe Flash Webcast
- Download any slides as Adobe Acrobat files
- Download any audio only as MP3s or Podcasts
|
Sessions can be individually reviewed for credit. You can participate in as few or as many as you desire.
CME-Accredited Educational Activity Dates and Time to Complete
Date of release: September 1, 2011
Date expires (CME credit will not be avaliable): September 1, 2012
Average time to complete each individual session: 20 minutes
Time to complete entire activity: 2 hours
Overview
This online activity reviews the new options for managing melanoma and basal cell carcinoma.
Educational Needs Summary
In 2010, the incidence of melanoma in the USA was an estimated 68,130 new cases with approximately 8,700 patients expected to have died of this malignancy. The majority of melanoma patients have early-stage disease that is often curable by surgically removing the malignancy from the skin but many patients require systemic therapy for their advanced or metastatic stages of this cancer. Patients with advanced or metastatic melanoma have a very poor prognosis, with a 5-year survival rate of only about 15%. No effective systemic therapeutic agents until very recently have been available for the treatment of advanced or metastatic melanoma. The FDA on March 25, 2011 approved the first new drug for melanoma in years, an anti-CTLA4 immunotherapy, ipilimumab, based upon improved survival in patients with this agent for managing patients with advanced or metastatic disease. Later in 2011, or in early 2012, the FDA is expected to approve a second drug, vemurafenib, an oral targeted therapy for melanoma patients with the BRAF V600 mutation. Vemurafenib is also used for advanced and metastatic melanoma patients and provides improved survival. Thus, a need exists to help oncologists and other clinicians treating and caring for patients with melanoma better understand which patients will benefit from which of these new and very different therapeutic strategies.
Basal cell carcinoma (BCC) is the most common form of skin cancer in the USA, comprising approximately 70% of all skin cancers and affecting approximately one to two million Americans each year. There is no standard therapy for locally advanced or metastatic BCC. The survival time with metastatic BCC varies widely, but the median is approximately eight months. For improving BCC patient outcomes, a novel targeted agent, vismodegib is currently in clinical development to treat inoperable BCC through inhibition of the hedgehog-signaling pathway.
Upon completion of this educational activity, participants should be able evaluate recent clinical data regarding the use of novel targeted and immunotherapeutic options under investigation for the treatment of advanced and metastatic melanoma, and similarly, evaluate data with novel targeted therapy for treating basal cell carcinoma.
The following is list of all sessions
| 1 |
2 CASE STUDIES: Targeting the BRAF pathway for melanoma: For which patients is this strategy the most useful to improve patient outcomes?
Keith T. Flaherty, MD
|
| 2 |
2 CASE STUDIES: Managing toxicities from BRAF Inhibition: How can these toxicities be managed to enable continuation of therapy?
Paul B. Chapman, MD
|
| 3 |
2 CASE STUDIES: CTLA-4 Blockade: Where is this immunologic strategy optimal for improving outcomes in melanoma patients and how can anti-CTLA-4 side effects be managed to enable continuation of therapy?
Jeffrey S. Weber, MD, PhD
|
| 4 |
CASE STUDY: Inhibiting the Hedgehog Pathway for improving outcomes in Basal Cell Carcinoma: How can patients benefit from this novel strategy? A dermatologist's perspective.
Aleksander Sekulic, MD, PhD
|
| 5 |
CASE STUDY: Inhibiting the Hedgehog Pathway for improving outcomes in Basal Cell Carcinoma: How can patients benefit from this novel strategy? A medical oncologist's perspective.
Patricia M. LoRusso, DO
|
| 6 |
Roundtable Panel Discussion and Audience Q & A
Faculty
|
|
|
|
Educational Objectives
At the conclusion of all of these enduring materials, you should be able to:
- Devise strategies for personalizing therapy to improve outcomes in patients with advanced and metastatic melanoma and basal cell carcinoma.
- Describe the evidence-based data for improving overall and progression-free survival in previously untreated patients with advanced and metastatic melanoma using BRAF inhibition.
- Devise strategies to apply the most current scientific and clinical data supporting the utilization of CTLA-4 immunotherapy for the treatment of melanoma.
- Develop strategies to successfully manage the unique side effects or immune-related Adverse Events resulting from CTLA-4 immunotherapy.
- Compare and contrast strategies for improving survival outcomes in advanced and metastatic melanoma patients with targeted therapy versus immunotherapy.
- Explain and apply the various strategies to manage therapy-related toxicities with BRAF inhibition for melanoma patients.
- Examine and apply the scientific and biologic rationale regarding inhibition of the hedgehog pathway for personalized treatment of basal cell carcinoma.
Target Audience
This activity is designed to help medical oncologists, hematologists, dermatologists, surgical oncologists, and other allied health-care professionals involved in the management of patients with skin cancers, including physician assistants, nurse practitioners/nurses, pharmacists, and fellows, close Practice Gaps related to treating their patients with cutaneous malignancies. Skin cancers are managed optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to this live CME-accredited activity.
CME Accreditation & Credit Designation
The Biomedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Biomedical Learning Institute designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME Certificate or Certificate of Participation
The relevant section(s) of the Evaluation Form pertaining to the session(s) of the enduring materials you have viewed or listened to, and the Request for Credit Form must be completed and submitted to the Biomedical Learning Institute following your participation in the enduring material educational activity to obtain CME credit. Physicians and other participants will be able to print their certificates after they complete these Forms.
|
|
Faculty Affiliations and Disclosures
Keith T. Flaherty, MD (Co-Chair)
Director, Developmental Therapeutics
Lecturer, Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, MA
Consulting Fees: Roche/Genentech, Glaxo Smith Kline
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
|
Patricia M. LoRusso, DO (Co-Chair)
Professor of Medicine
Chief Researcher
Director, Phase I Clinical Trials
Barbara Ann Karmanos Cancer Institute
Wayne State University
Detroit, MI
Consulting Fees: Genentech
Fees for Non-CME Services Received Directly from Commercial Interest: Genentech
|
Paul B. Chapman MD
Attending Physician
Melanoma/Sarcoma Service,
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
Contracted Research: Hoffman-LaRoche, Genentech, GlaxoSmithKline
Ownership Interest: Allergen
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
|
Jeffery S. Weber MD PhD
Director, Donald A. Adam
Comprehensive Melanoma Research Center
Senior Member, Moffitt Cancer Center
Professor and Associate Chair
Department of Oncologic Sciences
University of South Florida
Tampa, FL
Consulting Fees: Genentech Bristol-Myers Squibb, Genetech
Patent Holder: Medarex
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
Aleksander Sekulic, MD, PhD
Assistant Professor
Department of Dermatology
Mayo Clinic
Scottsdale, AZ
I have no real or apparent conflicts of interest to report.
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
|
|
|
Peer Review Process of Conflicts of Interest
This educational activity has been independently peer-reviewed.
Disclosure of Unlabeled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians' Desk Reference.
The Biomedical Learning Institute (BMLI) does not recommend the use of any agent outside of the FDA labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the BMLI. Please refer to the official FDA prescribing information for each product for discussion of approved indicated, contraindications, and warnings.
Acknowledgement of Supporters
| Educational Grants |
Sincere appreciation is extended to the following companies for their generous support of this educational meeting: |
 |
 |
|
